

Effective Date	3/15/2024
Next Review Date	3/15/2025
Coverage Policy Number	IP0272

# **Glucose Test Strips**

Overview	1
Medical Necessity Criteria	1
Reauthorization Criteria	2
Authorization Duration	2
Conditions Not Covered	2
Background	2
References	

# Related Coverage Resources

#### INSTRUCTIONS FOR USE

Table of Contents

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

#### **Overview**

This policy supports medical necessity review for glucose test strip products.

Receipt of sample product does not satisfy any criteria requirements for coverage.

# **Medical Necessity Criteria**

Coverage criteria are listed for products in below table:

Non-Covered Product	Criteria
AccuChek®, Accutrend®,	Standard/Performance/Value/Advantage/Cigna Total Savings:
Advocate <sup>®</sup> , Agamatrix <sup>®</sup> ,	
Assure <sup>®</sup> , Careone <sup>®</sup> ,	Non-covered glucose test strips are medically necessary when there is
CareSens <sup>™</sup> , CareTouch <sup>®</sup> ,	documentation of inability to use <b>BOTH</b> One Touch Ultra® <b>AND</b> One Touch
Clever Choice <sup>™</sup> , Contour <sup>®</sup> ,	Verio <sup>®</sup> due to a physical limitation that makes utilization of the One Touch

Page 1 of 3

Coverage Policy Number: IP0272

Non-Covered Product	Criteria
Cool <sup>™</sup> , Diatrue Plus <sup>®</sup> , Easy Plus <sup>®</sup> , Easy Touch <sup>®</sup> , Easy Talk <sup>®</sup> , Easy Trak <sup>®</sup> , EasyGluco <sup>®</sup> , EasyMax <sup>®</sup> , Element <sup>™</sup> , Embrace <sup>®</sup> , EQ <sup>®</sup> , EvenCare <sup>®</sup> , Evolution <sup>®</sup> , EZ Smart, Fifty50 <sup>®</sup> , FORA <sup>®</sup> , FortisCare <sup>®</sup> , Freestyle <sup>®</sup> , GE100, GE333, Genstrip <sup>™</sup> , GlucoCom <sup>™</sup> , GNP Easy Touch <sup>®</sup> , Gojji <sup>®</sup> , Harmony <sup>™</sup> , HealthPro <sup>™</sup> , IGlucose <sup>®</sup> , Infinity <sup>®</sup> , Microdot <sup>®</sup> , MyGlucoHealth <sup>™</sup> , Neutek, NovaMax <sup>®</sup> , On Call <sup>®</sup> , Optium <sup>®</sup> , OptumRx, Pharmacist Choice <sup>™</sup> , Pip <sup>®</sup> , Precision <sup>™</sup> , Premium, Pro Voice <sup>®</sup> , Prodigy <sup>®</sup> , Quintet <sup>®</sup> , Refuah Plus, Relion <sup>™</sup> , Reveal, Rexall <sup>™</sup> , Righttest <sup>™</sup> , Smart Sense, SmartTest, Solus V2 <sup>™</sup> , Sure-Test, Telcare <sup>™</sup> , Test N'Go <sup>®</sup> , True Metrix <sup>®</sup> , Truetest <sup>™</sup> , TRUEtrack <sup>®</sup> , UltraTRAK <sup>™</sup> , UniStrip <sup>™</sup> , Up & Up <sup>™</sup> , V-R, VeraSens <sup>™</sup> , VivaGuard <sup>®</sup> Ino, WaveSense <sup>™</sup>	product not accurate, safe or for other reason not medically appropriate (for example, manual dexterity, visual impairment, or use of an insulin pump with a dedicated meter)
This list may not be all-inclusive	

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

### Reauthorization Criteria

Continuation of glucose test strip products is considered medically necessary when the above medical necessity criteria are met AND there is documentation of beneficial response.

## **Authorization Duration**

Initial approval duration: up to 12 months

Reauthorization approval duration: up to 12 months

# **Conditions Not Covered**

Any other use is considered experimental, investigational, or unproven.

### **Background**

Page 2 of 3

Coverage Policy Number: IP0272

#### **OVERVIEW**

There are a variety of blood glucose meters available on the market with varying features. However, most meters generally offer a small sample size, the ability to test at alternate sites (besides the fingertips) and have easily readable screens. For visually impaired patients, speaking meters are available from select manufacturers. There are a small number of blood glucose meters that interact wirelessly with a specific insulin pump providing data for basal and bolus insulin needs based on the blood glucose measurement. Various sources, including device manufacturers and the American Diabetes Association (ADA), maintain updated lists of available products, including their features and compatibility.<sup>1-7</sup>

Diabetic test strips are measured for accuracy using standards set forth by the International Organization for Standardization and/or FDA.<sup>8-10</sup> Currently marketed monitors must meet the standard under which they were approved.<sup>1</sup> The ADA Standards of Care (2023) acknowledge that monitoring of accuracy is left to the manufacturer and is not routinely checked by an independent source; there may be variation in accuracy of blood glucose monitoring systems. However, a preference is not made in the ADA Standards for any particular brand of test strip over others.

#### References

- 1. American Diabetes Association. Standards of medical care in diabetes 2023. *Diabetes Care*. 2023;46(Suppl 1):S1-S291.
- 2. Products. Abbott. Available at: https://www.diabetescare.abbott/products.html. Accessed on September 13, 2023.
- 3. Resources: Test Strip Compatibility. Ascensia Diabetes Care. Available at: https://www.contournextpro.com/resources/test-strip-compatibility/. Accessed on September 13, 2023.
- 4. One Touch® Test Strips. LifeScan. Available at: http://www.onetouch.com/our\_products. Accessed on September 13, 2023.
- 5. Accu-Chek® Test Strips. Roche Diabetes Care. Available at: https://www.accu-chek.com/products/blood-glucose-monitoring/test-strips. Accessed on September 15, 2022.
- 6. Blood Glucose Monitoring Systems. Trividia Health. Available at: https://trividiahealth.com/products/blood-glucose-meters-test-strips/. Accessed on September 13, 2023.
- 7. American Diabetes Association. Consumer Guide. Available at: https://consumerguide.diabetes.org/collections/meters. Accessed on September 13, 2023.
- 8. Krouwer JS and Cembrowski GS. A review of standards and statistics used to describe blood glucose monitor performance. *J Diabetes Sci Technol*. 2010;4(1):75-83.
- 9. Lazarte M. More accurate self-testing results for diabetes patients with new ISO standard. June 19, 2013. Available at: http://www.iso.org/iso/home/news\_index/news\_archive/news.htm?refid=Ref1749. Accessed on September 13, 2023.
- 10. US Department of Health and Human Services. Food and Drug Administration. Center for Devices and radiological health Office of In Vitro Diagnostic Device Evaluation and Radiological health. Division of Chemistry and Toxicology Devices. Self-monitoring blood glucose test systems for over-the-counter use. Guidance for industry and Food and Drug Administration Staff. September 2020. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM38 0327.pdf. Accessed on September 13, 2023.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2024 Cigna.